Modern biotechnology has made possible the rapid development and introduction into clinical care of a wide spectrum of potent antimicrobial agents. However, the battle against Streptococcus pneumoniae (pneumococcus) has remained fierce, as acquisition of resistance is even more rapid and these antimicrobial agents are rendered ineffective. Obtaining appropriate antibiotic treatment for severe invasive pneumococcal infections is now a major challenge in many regions of the world. The ground-breaking success of Haemophilus influenzae type b (Hib) conjugate vaccine has brought hope for the conquest of other capsulate bacteria. Recent results of efficacy trials of a heptavalent pneumococcal conjugate vaccine bring hope that protein conjugate vaccines will have a similar impact on pneumococcal disease. These multivalent vaccine formulations include pneumococcal serotypes that most often acquire antibiotic resistance and there is hope that the widespread application of these vaccines will decrease the
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.. This protocol posting deals with objectives & outcome measures of the primary study. The objectives & outcome measures of the Booster study are presented in a separate protocol posting (NCT number = 00609492) ...
Pneumococcal conjugate vaccine (PCV) is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (the pneumococcus). There are currently three types of PCV available on the global market, which go by the brand names: Prevnar (called Prevenar in some countries), Synflorix and Prevnar 13. Prevnar (PCV7) is a heptavalent vaccine, meaning that it contains the cell capsule sugars of seven serotypes of the bacteria S. pneumoniae (4, 6B, 9V, 14, 18C, 19F and 23F), conjugated with diphtheria proteins. It was manufactured by Wyeth (which has since been acquired by Pfizer). In the United States, vaccination with Prevnar is recommended for all children younger than 2 years, and for unvaccinated children between 24 and 59 months old who are at high risk for pneumococcal infections. Synflorix (PCV10) is produced by GlaxoSmithKline. It is a decavalent vaccine, meaning that it contains ten serotypes of ...
Anticoagulant medications and immunosuppressants may interfere with the pneumococcal conjugate vaccine. This eMedTV Web page describes some of the problems that may occur as the result of pneumococcal conjugate vaccine drug interactions.
We tested the hypothesis that conjugate vaccine offered less protection against pneumonia due to a reduced mucosal response compared to serum. We further hypothesized that this response would be further compromised with HIV co-infection[32] due to lack of local CD4 lymphocyte support and an altered alveolar milieu. We measured pneumococcal capsular specific immunoglobulin responses to 7-valent conjugate vaccine in both lung fluid and serum from healthy HIV infected and uninfected volunteers, together with flow cytometric assessment of the relative numbers and phenotypes of BAL T lymphocyte, B lymphocyte and macrophages ...
In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccines effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the countrys population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of
The aim of present study is to inverstigate the association between antibody levels after vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) and subsequent serious pneumococcal infections in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients. A cohort of 497 patients (RA = 248 and SpA = 249) received a single dose of PCV7. At vaccination, patients were treated with methotrexate (MTX; n = 85), anti-tumour necrosis factor (anti-TNF) + MTX (n = 169), anti-TNF monotherapy (n = 158) and non-steroidal anti-inflammatory drugs (NSAIDs)/analgesics (n = 85). Antibody levels of serotypes 6B and 23B were analyzed before and 4 to 6 weeks after vaccination using standard enzyme-linked immunosorbent assay (ELISA). Serious pneumococcal infections (pneumonia/lower respiratory tract infection, meningitis, sepsis, septic arthritis) occurring within 4.5 years after vaccination were identified in the Skåne Healthcare Register using the International Classification of Diseases, tenth revision (ICD
Background: Evaluation of children with fever without localising signs (FWLS) has barely changed in the USA since 1993 despite reduced invasive disease after the introduction of Haemophilus influenzae type b conjugate vaccine and conjugate pneumococcal vaccine (PCV7). PCV7 is now recommended in the UK for children under 2 years of age, and new NICE guidelines have been issued for managing feverish children in the UK in anticipation of PCV7s efficacy. We compared rates of bacterial infections in children aged 3-36 months with FWLS in the pre- and post-PCV7 eras to define current trends and evaluate existing guidelines. Methods: We identified all paediatric blood cultures performed in an emergency department before and after PCV7. We subsequently identified all children aged 3-36 months with FWLS and reviewed their medical records. Results: We identified 148 patients with FWLS in the pre-PCV7 period and 275 patients after PCV7. There were 17 positive cultures before PCV7 (10 pathogens and seven ...
BACKGROUND: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM197 was evaluated in a randomized, double-blind, controlled infant study. METHODS: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). Specific antibody responses were assessed at age 5, 12, and 13 months. RESULTS: At 13 months of age, |97% of PCV13 recipients had pneumococcal serotype-specific serum IgG concentrations ≥0.35 µg/mL for each vaccine serotype except serotype 3 (88.2%), and at least 93% of PCV13 recipients had OPA titers ≥1:8 for each serotype. At 5 months, 110/114 (96.5%) of PCV13 recipients and 100/102 (98.0%) of PCV7 recipients
BACKGROUND: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM197 was evaluated in a randomized, double-blind, controlled infant study. METHODS: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). Specific antibody responses were assessed at age 5, 12, and 13 months. RESULTS: At 13 months of age, |97% of PCV13 recipients had pneumococcal serotype-specific serum IgG concentrations ≥0.35 µg/mL for each vaccine serotype except serotype 3 (88.2%), and at least 93% of PCV13 recipients had OPA titers ≥1:8 for each serotype. At 5 months, 110/114 (96.5%) of PCV13 recipients and 100/102 (98.0%) of PCV7 recipients
Rekomendasi Imunisasi Meningococcal Conjugate Vaccine (MCV) Rekomendasi terbaru vaksin meningokokus telah dikeluarkan oleh American Association of Pediatrics, komite AAP bagian penyakit menular dan Advisory Committee on Immunization Practices dari Centers for Disease Control and Prevention (CDC). Rekomendasi terbaru tersebut menyarankan pemberian sejak usia 9 bulan pada kelompok resiko tinggi dengan pemberian vaksinasi MCV4. Rekomendasi tsebelumnya juga menyarankan…
Booy, R, Richmond, P, Nolan, T et al 2013, Three-Year Antibody Persistence and Safety following a Single Dose of Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Hib-Primed Toddlers, The Pediatric Infectious Disease Journal, vol. 32, no. 2, pp. 169-174.. Lambert, S, Chuk, L, Nissen, M et al 2013, Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents, Influenza and Other Respiratory Viruses, vol. 7, no. 5, pp. 676-685.. McVernon, J, Nolan, T, Richmond, P et al 2012, A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers, The Pediatric Infectious Disease Journal, vol. 31, no. 1, pp. E15-E23.. Marshall, H, Richmond, P, Nissen, M et al 2012, Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged ...
See risks and benefits. Visit the official website for the vaccine PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) for adults.
Read about PREVNAR 13® Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), a vaccine for adults 18 years of age & older. See risks & benefits.
BACKGROUND AND AIMS: Serogroup A, C, W-135 and Y meningococcal (MenACWY) conjugate vaccines are recommended for routine adolescent immunisation in the United States and Canada. We evaluated the persistence of bactericidal antibodies through early childhood, following infant immunisation with varying schedules of MenACWY-CRM(197) vaccine. METHODS: UK and Canadian infants were immunised with 2-3 doses of MenACWY-CRM(197) or 2 doses of serogroup C meningococcal (MenC) conjugate vaccine, and either MenACWY-CRM(197), 1/5 dose of MenACWY polysaccharide vaccine or no booster at 12 months. Control groups recruited at 60 months had received country-specific infant doses of MenC conjugate vaccine. hSBA titres were measured in participants at 40 and 60 months of age. RESULTS: 382 children were enrolled in 12 groups (22-40 per group). By age 60 months, 3-11% of children primed and boosted with MenACWY-CRM(197) had hSBA titres|/=1:8 against serogroup A, 14-45% against serogroup C, 57-85% against serogroup W-135 and
This is a reminder that if your senior student has not had their 2nd meningococcal conjugate vaccine, they are currently on a 60 day provisional certificate from the date of registration. After October 15, they will be excluded from school until proof of vaccine is received. Phone calls have been made and letters have been mailed to identified students parents. Please make the appointment as soon as possible and have your senior bring proof of immunization to the health office. Any questions may be directed to the health office at 712-366-8272. ...
A new Illinois law requires any student considered a senior at LPHS to show proof of having had two doses of a meningococcal conjugate vaccine. If the first dose was given after age sixteen only one ...
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines Polysaccharide-encapsulated organisms are the leading cause of bacterial meningitis and pneumonia in children. The use of protein-polysaccharide conjugate vaccines in developed countries over the past two decades has markedly decreased the burden of disease and mortality from these organisms through direct protection of the immunized and…
This study reports the antibody persistence in healthy children up to 5 years after the Hib and MenC full vaccination course. At the time the study was conducted, children in the United Kingdom used to receive concomitant doses of Hib-MenC and pneumococcal conjugate vaccines as primary vaccinations. Our data are important in comparing persistence after booster vaccination, since children in the United Kingdom currently receive booster doses of Hib-MenC and pneumococcal conjugate vaccines simultaneously at 12 to 13 months of age (35).. For MenC, the percentages of children retaining seroprotective rSBA-MenC titers at year 5 after booster vaccination were 24.2%, 25.4%, 38.5%, and 40.1% in the MenC-CRM, Hib-MenC + 7vCRM, Hib-MenC + PHiD-CV, and MenC-TT groups, respectively. In contrast, retention of anti-PRP antibodies was nearly universal in all groups; at least 98.5% of children in each group were observed to have anti-PRP concentrations of ≥0.15 μg/ml at 5 years after booster ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Pneumococcal protein-polysaccharide conjugate vaccines provide direct protection against Streptococcus pneumoniae through the induction of persistent anti-polysaccharide antibodies, and by priming for a rapid secondary antibody response. Memory B cells (BMEM) generated during an initial immune response are responsible for both the more rapid and quantitatively greater secondary antibody response and are also thought to contribute to the ongoing production of plasma cells providing long-term antibody persistence. We recruited 3.5-year-old children who had participated in a previous clinical trial comparing infant immunization with either a 7-valent (PCV-7) or a 13-valent pneumococcal conjugate vaccine (PCV-13) to investigate whether prior priming with pneumococcal antigens influences BMEM responses. Blood was taken before and 1month after a PCV-13 booster. BMEM were quantified using a cultured ELISpot assay for pneumococcal serotypes 1, 3, 4, 14, 19A, 23F, and with diphtheria and tetanus toxoid as
Bacteria use numerous strategies to avoid innate and acquired host defenses and maintain their capacity to cause serious infections. One well-known strategy is illuminated by the poor immune response of human infants and young children to polysaccharide antigens, which are major protective antigens for many bacterial pathogens. However, by conjugating polysaccharides to protein carriers this immunologic barrier can be broken, and effective conjugate vaccines to Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis have been developed (3, 19, 54). Another strategy pathogens use to avoid host immune effectors is to elicit high levels of poorly protective antibodies, which can have this property based on low antibody affinity, production of an inappropriate antibody isotype, or specificity for nonprotective epitopes (32, 37, 46). In the case of the PNAG antigen, it appears that both poor overall immunogenicity of the native polysaccharide and a preferential induction of ...
There is great interest in the use of reduced dosing schedules for pneumococcal conjugate vaccines, a strategy premised on maintaining an acceptable level of protection against disease and carriage of the organism. We asked about the practicality of measuring differential effectiveness against carriage in a population with and without widespread use of the vaccine for infants. We adapted an existing transmission-dynamic, individual-based stochastic model fitted to the prevaccine epidemiology of pneumococcal carriage in the United States, and compared the observed vaccine-type carriage prevalence in different arms of a simulated trial with one, two, or three infant doses plus a 12-month booster. Using these simulations, we calculated vaccine efficacy that would be estimated at different times post-enrollment in the trial and calculated required sample sizes to see a difference in carriage prevalence. In a pneumococcal conjugate vaccine (PCV)-naïve population, the difference in vaccine-type (VT)
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Graphical Abstract type b conjugate vaccine and pneumococcal conjugate vaccine at 12 to15 months of age, and diphtheria, tetanus, acellular pertussis (DTaP) vaccine at 15 to 18 months of age, as long as doses were given at least 8 days after and at least 4 weeks before a dose of the study vaccine. Measles, mumps, rubella (MMR) and varicella vaccines were allowed if administered at least 4 weeks before or after administration of the study vaccine. Study vaccine LAJEV (CD-JEVAX?, Chengdu Institute of Biological Products, Chengdu, China) was used in this study. The main component of this vaccine is usually SA14-14-2 strain of JE computer virus. The others are lactose, sucrose, gelatin, human blood albumin and urea. Each subject was administered 0.5 mL of freshly reconstituted vaccine subcutaneously to the upper arm as instructed by the manufacturer. Immunogenicity evaluation Blood ...
PREVNAR 13 medication page for healthcare professionals to search for scientific information on Pfizer medications. Also find the package insert, announcements, resources, and ways to connect with Pfizer Medical through a variety of channels.
A combination vaccine offered to mothers from 28 weeks of gestation may offer protection for infants born prematurely, according to a study published online June 2 in Pediatrics.
We will use appropriate corrections to reduce the probability required to accept statistical significance. Geometric means of the antibody concentrations (GMC) of ELISA (micro-gram/millilitre) and geometric mean titers (GMT) of OPA (titer-1) at each of the five visits and geometric mean fold rise (GMR) between visits will be calculated within each treatment group for each of the 7 pneumococcal serotypes (4,6B, 9V, 14, 18C, 19F and 23F), and 95% confidence intervals will be constructed by back transformation of the confidence intervals for the mean of the log transformed assay results computed using the Student t distribution. Comparisons of geometric mean antibody concentrations and titers measured by ELISA and OPA, respectively, between the immunization groups were performed by unpaired 2-tailed t-test for parametric analyses and Wilcoxon rank sum test for non-parametric analyses. Based on changes of GMC of ELISA and GMT of OPA at five time points (visits), the rate of wanning immunity can be ...
See risks and benefits. Pneumococcal pneumonia is a potentially serious lung disease caused by a common bacteria that can spread fast through a cough or close contact.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
A phase III, randomized, single-blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate vaccine as a 3-dose primary immunization course at 6, 10 and 14 weeks of age in India, co-administered with GSK Biologicals Tritanrix-HepB/Hib (DTPw-HBV/Hib) vaccine ...
http://www.radiantinsights.com/research/global-conjugate-vaccines-2021/request-sample. As per the sign of sickness, the vaccines market sections are influenza, tetanus, diphtheria and pertussis (DTP), pneumococcal disease, varicella, hepatitis, meningococcal disease, rotavirus, measles, mumps and rubella (MMR), polio, human papilloma virus (HPV) infection, and others. The pneumococcal sickness section was projected to describe the biggest stake of the international market in 2016. High occurrence of pneumococcal contaminations and the necessity for injections to avoid the sickness strengthens the progress of market of this section.. Final consumers, comprised in the vaccines market are pediatrics and adults. The pediatrics section was expected to justify for the biggest stake of the international market in 2016. Increasing amount of alertness series to encourage vaccination has caused in the growing usage of vaccines for pediatrics. On the basis of geography, the vaccines market is ruled by ...
http://www.radiantinsights.com/research/global-conjugate-vaccines-2021/request-sample. As per the sign of sickness, the vaccines market sections are influenza, tetanus, diphtheria and pertussis (DTP), pneumococcal disease, varicella, hepatitis, meningococcal disease, rotavirus, measles, mumps and rubella (MMR), polio, human papilloma virus (HPV) infection, and others. The pneumococcal sickness section was projected to describe the biggest stake of the international market in 2016. High occurrence of pneumococcal contaminations and the necessity for injections to avoid the sickness strengthens the progress of market of this section.. Final consumers, comprised in the vaccines market are pediatrics and adults. The pediatrics section was expected to justify for the biggest stake of the international market in 2016. Increasing amount of alertness series to encourage vaccination has caused in the growing usage of vaccines for pediatrics. On the basis of geography, the vaccines market is ruled by ...
Pfizer Inc. (PFE) Monday said the phase 3 study of its Pneumococcal conjugate vaccine - Prevnar 13 met all endpoints, showing immunogenicity and safety in children and adolescents aged 5 through 17 years.
Originally from the United Kingdom, as a child Dr. Harold Jennings was drawn to science and loved to mix substances in his home chemistry set.. This love of science led him to several decades of research and development of a successful vaccine against meningitis C, a serious bacterial infection with potentially fatal consequences. Meningitis is an infection of the fluid and lining of the brain and spinal cord, which can lead to death, hearing loss, cognitive deficits and loss of limbs.. Dr. Jennings and his team were the first to patent a method that chemically combines the complex sugars that cover the surface of Group C meningitis with a protein. This technique eventually led to the development of a combined "conjugate" vaccine that continues to save lives here in Canada and around the world. Through Dr. Jennings continued and persistent efforts, NeisVac‑C-the conjugate vaccine he developed for immunizing both children and adults against Group C meningococcal meningitis-became commercially ...
Infections with polysaccharide (PS)-encapsulated extracellular bacteria are a major source of global morbidity and mortality among infants, as well as the elderly and immunosuppressed individuals. An understanding of the immunological basis of glycoconjugate interactions is still emerging but is already helping shape strategies to improve conjugate responses. Genetic factors in humans that are known to influence susceptibility to infection with the pneumococcus may also provide a clue to the key factors associated with the immune response to PS antigens. The covalent linkage of PS antigens to immunogenic proteins capable of recruiting CD4+ T-cell help to produce conjugate vaccine, first described in the 1930s, results in the elicitation of protective, high-titer-IgG anti-PS responses and the generation of immunologic memory, as well as immunogenicity in the infant host. Conjugate vaccines used clinically are produced by employing a limited number of carrier proteins (e.g., tetanus toxoid (TT),
Today the University of Maryland School of Medicines Center for Vaccine Development is proud to be part of vaccine history in Africa.
Pneumococcal conjugate vaccine recommended for use in adults with conditions that affect immune system, including HIV infection and cancer
JNs research and development organization draws upon expertise in multiple discovery plat-forms. This means that, in addition to traditional small molecules, we are sharply focused on biologics. We have outlined a number of early-stage development that include three novel CNS vaccines and diagnostics to fight Stroke and Alzheimers diseases. We also have programs progressing through development that seek to expand existing products with newly identified uses and indications. We are hopeful for U.S. approval in 2017 for Meningococcal conjugate vaccine and our human trial outcome will be reviewed at an FDA advisory committee meeting. ...
Meningococcal conjugate vaccine protects against some of the bacteria that can cause meningitis (swelling of the lining around the brain and spinal cord) and sepsis (an infection in the blood). Meningitis can be very serious, even fatal. Preteens need the MCV4 shot when they are 11 or 12 years old and then a booster shot at age 16. Teens who got the MCV4 shot when they were 13, 14, or 15 years old should still get a booster at 16 years. Older teens who havent gotten any MCV4 shots should get one as soon as possible ...
In conventional conjugate vaccines, proteins act as carriers for polysaccharides that induce an immune response. But what if those proteins could induce an immune response, too?
/PRNewswire/ -- SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to...
Having trouble viewing this email? View it as a Web page. Whats New at CBER You are subscribed to Whats New at CBER for the U.S. Food & Drug Administration (FDA). This page has been updated recently. Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular…
Research Interest. We strive to exploit the power of synthetic small molecules for development of tools for glycomics/glycoproteomics, carbohydrate-based inhibitors, and synthetic oligosaccharide-based conjugate vaccines. Using chemical biology approaches we are investigating structure-function relationships of glycoforms of leukocyte antigens, engineering of glycans in central nervous system (CNS), and glycopeptidomimetics based anti-metastatic agents.. Group Members. Ms. Surbhi Goswami, Ms. Vandita Dwivedi, Ms. Pratima Saini, Ms. Ahana Addhya, Ms. Anam Tasneem, Mr. Shubham Parashar, and Ms. Charu Chauhan. Technical Support - Ms. Archana Ranjan, Mr. Mohd. Aslam, Mr. P. Rajkumar. Past Members - Dr. Kavita Agarwal, Dr. Asif Shajahan, Dr. Syed Meheboob Ahmed, Dr. Rachna Kaul, Ms. Monika Garg, Ms. Deepshikha Singh, Ms. Priti Singh, Ms. Hemaswasthi, Mr. Saroj Kumar Jha, Mr. Sebanta (Sanjay) Pokhrel, Mr. Arnob Nandi.. Summary of Research. We are interested in the investigation of the ...
In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other quadrivalent meningococcal conjugate vaccine, MenACWY-D(Menactra, Sanofi Pasteur), is licensed in the United States for prevention of meningococcal disease caused by serogroups A, C, Y, and W-135 among persons aged 2 through 55 years; MenACWY-D also is licensed as a 2-dose series for children aged 9 through 23 months (1,2). The Advisory Committee on Immunization Practices (ACIP) recommends that persons aged 2 through 55 years at increased risk for meningococcal disease and all adolescents aged 11 through 18 years be immunized with meningococcal conjugate vaccine. ACIP further recommended, in January 2011, that all adolescents receive a booster dose of quadrivalent meningococcal conjugate vaccine at age 16 years (3). This report summarizes data ...
CDC: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP ...
This thesis addresses various aspects on pneumococcal disease, pneumococcal conjugate vaccines (PCVs) and the societal impact of PCV implementation in children. Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) in the Dutch national immunization program for infants led to a shift from vaccine to non-vaccine serotypes (i.e. replacement disease) in invasive ... read more pneumococcal disease (IPD). This shift was observed in all age groups, including non-vaccinated persons, due to indirect effects.Indirect were caused by a reduction in nasopharyngeal colonization of vaccine serotypes in children and subsequent transmission (i.e. herd effects). Also after PCV7 was replaced by a 10-valent pneumococcal conjugate vaccine (PCV10) we observed herd effects for extra serotypes covered by PCV10.Replacement disease following PCVs was primarily caused by expansion of pre-existing non-vaccine serotypes (NVT) rather than capsular switch variants.Despite replacement disease IPD incidence has ...
TY - JOUR. T1 - Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010-2017. AU - Invasive Pneumococcal Diseases Surveillance Study Group. AU - Ubukata, Kimiko. AU - Takata, Misako. AU - Morozumi, Miyuki. AU - Chiba, Naoko. AU - Wajima, Takeaki. AU - Hanada, Shigeo. AU - Shouji, Michi. AU - Sakuma, Megumi. AU - Iwata, Satoshi. PY - 2018/11/1. Y1 - 2018/11/1. N2 - To clarify year-to-year changes in capsular serotypes, resistance genotypes, and multilocus sequence types of Streptococcus pneumoniae, we compared isolates collected from patients with invasive pneumococcal disease before and after introductions of 7-and 13-valent pneumococcal conjugate vaccines (PCV7 and PVC13, respectively). From April 2010 through March 2017, we collected 2,856 isolates from children and adults throughout Japan. Proportions of PCV13 serotypes among children decreased from 89.0% in fiscal year 2010 to 12.1% in fiscal year 2016 and among adults from 74.1% to ...
BackgroundThirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active immunization against Streptococcus pneumoniae causing invasive pneumococcal disease in infants and children. PCV13 offers broader protection against Streptococcus pneumoniae; however, PCV10 offers potential protection against non-typeable Haemophilus influenza (NTHi). We examined public health and economic impacts of a PCV10 and PCV13 pediatric national immunization programs (NIPs) in Canada.